Ad Scientiam reports positive 1-year interim data for MSCopilot at EAN 2026

Ad Scientiam said interim results from two Sanofi-supported studies show MSCopilot can track multiple sclerosis progression over one year and may be easier to deploy in routine care. The findings were presented in Geneva at the European Academy of Neurology Congress and could support use in both trials and long-term monitoring.

Why it matters: - Ad Scientiam is trying to prove that MSCopilot can do more than collect patient-reported data. The company wants the digital biomarker to measure multiple sclerosis progression reliably over time. - Stronger evidence could expand MSCopilot’s use in clinical trials and in routine care for people with MS. - Better remote monitoring could give clinicians more objective data between office visits and help track disability accumulation earlier.

What happened: - Ad Scientiam presented interim findings from the ongoing MS-DETECT and MS-FLOWER studies at the European Academy of Neurology Congress in Geneva. - Prof. Patrick Vermersch delivered an oral presentation on MS-DETECT on June 28, 2026. - Dr. Loïc Carment, chief scientific officer at Ad Scientiam, presented an ePoster on MS-FLOWER on June 29, 2026. - Ad Scientiam said the studies are supported by Sanofi.

The details: - The interim MS-DETECT analysis showed a consistent cross-sectional and longitudinal relationship over one year between MSCopilot digital tests and their related clinical gold standards. - Ad Scientiam said the study found a strong correlation between MSCopilot’s composite score and the Multiple Sclerosis Functional Composite, or MSFC. - The company said the results support MSCopilot’s reliability for tracking disease progression over time. - MS-FLOWER examined barriers to clinical adoption across four multiple sclerosis centers in the United States. - Ad Scientiam said the findings from MS-FLOWER will help speed deployment of MSCopilot into standard clinical workflows in the U.S. and Europe. - MSCopilot is a FDA-registered and CE-marked class IIa Software as a Medical Device. - The product lets people with multiple sclerosis independently assess walking capacity, manual dexterity, cognitive function and low-contrast visual acuity. - Results are shared with healthcare providers through a secure dashboard for structured and continuous care management.

Between the lines: - The MS-DETECT readout addresses a key question for digital biomarkers: whether unsupervised testing in a patient’s environment can stay aligned with established clinical measures. - The MS-FLOWER pilot suggests Ad Scientiam is also working on the operational side of adoption, not just the science. - If both validation and workflow issues hold up, MSCopilot could be positioned as a tool for both research endpoints and real-world monitoring. - Ad Scientiam framed the results as a step toward prospective real-world evidence cohorts and broader use in standard care.

What's next: - The company is continuing the MS-DETECT and MS-FLOWER studies. - Ad Scientiam expects the operational insights from MS-FLOWER to support broader rollout in key markets. - Future work will likely focus on expanding evidence for MSCopilot in clinical trials and routine MS care. - Ad Scientiam also says it is validating new medical devices in neuroscience, rare diseases and mental health.

The bottom line: - Ad Scientiam now has early data it says links MSCopilot to established clinical measures over a full year, while also mapping out how to bring the tool into everyday MS care.